Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643.
This review examines the various effects of Wy14,643, a hypolipidemic agent that activates peroxisome proliferator-activated receptor-alpha (PPARalpha), on the cardiovascular system. An emphasis has been placed on the specific cellular processes affected by Wy14,643 as they relate to vascular and cardiac function. Although the topic of this discussion is limited to vascular and cardiac tissues, the importance of circulating lipids on cardiovascular disease requires that a description of the indirect actions of this compound on liver metabolism also be included. Finally, the pharmacology of Wy14,643 is discussed within the context of PPARalpha-dependent and -independent mechanisms.
Zahradka
Peter
P
Institute of Cardiovascular Sciences, Department of Physiology, University of Manitoba and Canadian Centre for Agri-food Research in Health and Medicine, St. Boniface General Hospital Research Centre, Winnipeg, MB, Canada. peterz@sbrc.ca
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000503:physiopathology*; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D006973:Hypertension / Q000150:complications; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D020025:Peroxisome Proliferators / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D000960:Hypolipidemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; D020025:Peroxisome Proliferators; D011743:Pyrimidines; C006253:pirinixic acid